|
Market Closed -
Other stock markets
|
Pre-market 06:18:01 | |||
| 4.120 EUR | +2.28% |
|
4.110 | -0.24% |
| 02-03 | Global markets live: SpaceX, Tesla, Boeing, PayPal, AstraZeneca… |  |
| 02-03 | Valneva, Instituto Butantan Start Pilot Program for Chikungunya Vaccine in Brazil | MT |
Company Valuation: Valneva
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 704.9 | 2,574 | 861.1 | 655.1 | 351.1 | 715.9 | 715.9 | - |
| Change | - | 265.2% | -66.55% | -23.93% | -46.4% | 103.89% | 0% | - |
| Enterprise Value (EV) 1 | 553.9 | 2,286 | 670.5 | 737.8 | 399.1 | 803.7 | 848.3 | 828.9 |
| Change | - | 312.67% | -70.66% | 10.04% | -45.9% | 101.36% | 5.55% | -2.3% |
| P/E ratio | -10.9x | -32.7x | -5.02x | -6.47x | -27x | -8.2x | -13.5x | 10.2x |
| PBR | 9.09x | 15.1x | - | 5.1x | 1.94x | 5.36x | 7.72x | 4.39x |
| PEG | - | -5.8x | -0.1x | 0.2x | 0.3x | -0x | 0.3x | -0x |
| Capitalization / Revenue | 6.39x | 7.4x | 2.38x | 4.26x | 2.07x | 4.22x | 3.89x | 2.07x |
| EV / Revenue | 5.02x | 6.57x | 1.86x | 4.8x | 2.35x | 4.74x | 4.6x | 2.4x |
| EV / EBITDA | -12.3x | -48.5x | -9.69x | -11.3x | 12.1x | -16.6x | -35.1x | 9.48x |
| EV / EBIT | -10x | -37.2x | -5.91x | -8.99x | 29.9x | -12.2x | -19.4x | 12.3x |
| EV / FCF | 4.68x | -140x | -2.44x | -3.4x | -4.92x | -11.4x | -17.6x | 19.9x |
| FCF Yield | 21.4% | -0.71% | -41% | -29.4% | -20.3% | -8.76% | -5.67% | 5.03% |
| Dividend per Share 2 | - | - | - | - | - | - | 1 | 2 |
| Rate of return | - | - | - | - | - | - | 24.3% | 48.5% |
| EPS 2 | -0.71 | -0.75 | -1.24 | -0.73 | -0.08 | -0.5022 | -0.3052 | 0.4022 |
| Distribution rate | - | - | - | - | - | - | -328% | 497% |
| Net sales 1 | 110.3 | 348.1 | 361.3 | 153.7 | 169.6 | 169.6 | 184.2 | 345.5 |
| EBITDA 1 | -45.2 | -47.1 | -69.2 | -65.24 | 32.92 | -48.52 | -24.14 | 87.4 |
| EBIT 1 | -55.12 | -61.4 | -113.4 | -82.09 | 13.33 | -65.89 | -43.78 | 67.2 |
| Net income 1 | -64.4 | -73.4 | -143.3 | -101.4 | -12.25 | -82.66 | -55.17 | 70.06 |
| Net Debt 1 | -151.1 | -288.9 | -190.6 | 82.74 | 48.04 | 87.87 | 132.5 | 113 |
| Reference price 2 | 7.750 | 24.500 | 6.224 | 4.720 | 2.162 | 4.120 | 4.120 | 4.120 |
| Nbr of stocks (in thousands) | 90,958 | 105,078 | 138,355 | 138,788 | 162,397 | 173,753 | 173,753 | - |
| Announcement Date | 25/02/21 | 03/02/22 | 23/03/23 | 21/03/24 | 20/03/25 | - | - | - |
1EUR in Million2EUR
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -8.02x | 4.65x | -16.24x | - | 852M | |
| 36.2x | 5.26x | 17.62x | 0.95% | 47.17B | |
| 108.48x | 6.96x | 69.61x | -.--% | 38.6B | |
| 58.42x | 11.94x | 33.41x | 0.33% | 34.53B | |
| 26.51x | 2.79x | 11.94x | -.--% | 32.68B | |
| -17.45x | 4983.42x | -16.28x | -.--% | 18.7B | |
| 36.62x | 5.92x | 26.9x | -.--% | 14.94B | |
| Average | 34.39x | 717.28x | 18.14x | 0.21% | 26.78B | |
| Weighted average by Cap. | 47.97x | 503.06x | 27.45x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- VLA Stock
- Valuation Valneva
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition